Qualigen Therapeutics Inc (QLGN) has issued an announcement.
Qualigen Therapeutics, Inc. has struck a deal with Alpha Capital Anstalt, securing a $500,000 investment through a Securities Purchase Agreement. Alpha will receive an 8% Convertible Debenture and a 5-year warrant to purchase company stock, with provisions for price adjustments and beneficial ownership limits. Additionally, Alpha has the option to further invest $1 million for additional Debentures and Warrants, potentially influencing the conversion terms of existing securities. This strategic financial move aims to bolster Qualigen’s capital, offering Alpha registration rights and flexible repayment options on existing debt with the possibility of equity-based payments.
Find detailed analytics on QLGN stock on TipRanks’ Stock Analysis page.
